Heidi Rehm
@heidirehm.bsky.social
1.9K followers
85 following
16 posts
Genomic medicine researcher; chief genomics officer at MGH; clinical lab director at @broadinstitute
Posts
Media
Videos
Starter Packs
Heidi Rehm
@heidirehm.bsky.social
· Jul 6
Reposted by Heidi Rehm
Heidi Rehm
@heidirehm.bsky.social
· May 24
Reposted by Heidi Rehm
Doug Fowler
@dougfowler.bsky.social
· May 15
Atlas of Variant Effects 2030 Roadmap: resolving human variants of uncertain significance
At the Clinical Atlas of Variant Effects meeting (CLAVE meeting, July 2024, Pittsburgh USA), we developed recommendations for a draft atlas that can be realized by 2030, with a focus on empowering gen...
zenodo.org
Heidi Rehm
@heidirehm.bsky.social
· May 6
Reposted by Heidi Rehm
Daniel MacArthur
@dgmacarthur.bsky.social
· Mar 15
Evidence Aggregator: AI reasoning applied to rare disease diagnostics
Retrieving, reviewing, and synthesizing technical information can be time-consuming and challenging, particularly when requiring specialized expertise, as is the case of variant assessment for rare di...
www.biorxiv.org
Reposted by Heidi Rehm
Reposted by Heidi Rehm
Reposted by Heidi Rehm
Heidi Rehm
@heidirehm.bsky.social
· Nov 15
Heidi Rehm
@heidirehm.bsky.social
· Nov 14
Heidi Rehm
@heidirehm.bsky.social
· Nov 14
Distinct rates of VUS reclassification are observed when subclassifying VUS by evidence level
Purpose: Genetic testing commonly yields a plethora of variants of uncertain significance (VUS) that can lead to ongoing uncertainty for patients and their caregivers. While all VUS hold uncertainty,…
buff.ly
Heidi Rehm
@heidirehm.bsky.social
· Nov 1